lobbying_activities: 3963990

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	is_no_activity	is_termination	received_date
3963990	29a1f11a-d0e7-457c-90c9-e999a1ff4b84	Q2	LMH STRATEGIC SOLUTIONS	401108183	ALKERMES, INC.	2026	second_quarter	MMM	Medicare/Medicaid issues. Medicaid drug rebate program. Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. H.R.946: ORPHAN Cures Act. Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically. Provide guidance and advice regarding mental health, public health and regulatory reform.	Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE	0	0	2026-07-05T05:48:44-04:00